The fact that JGL made a great leap in modernising production processes by introducing continuous production at its new location Svilno 2, thus recognising the direction of the pharmaceutical business, was also confirmed last month in Belgrade. This was the location where the second QP conference was held from 1 to 2 October. The conference entitled “QP challenges in modern pharmaceutical business” included the participation of renowned speakers from abroad.
Changes and updates regarding the EU GMP regulations, pharmaceutical industry trends and QP responsibilities were presented at the conference, and interesting workshops with practical examples were held. Mate Poropat, the executive director for pharmaceutical technical operations, held a well-received lecture with the topic “Continuous production and marketing” on behalf of JGL, presenting the company to numerous experts and providing a broad view of continuous aerosol production.
Each medicine batch must be produced and analysed in accordance with defined procedures, the authorised registration documentation, good manufacturing practice (GMP regulations) and national legislation, as well as certified by the qualified person (QP) for marketing the medicine batch. The certification of the marketable batch in continuous production is based on the knowledge of production and product characteristics, controlling the production process, and parameter results that are tested during production.
The lecture garnered great interest and praise from the profession, and once again confirmed that JGL is a pharmaceutical company that invests in the production and quality system by following the trends and updates of the EU GMP regulations.